Renue By Science NMN 250mg SLC Enteric (Delayed Release) Review

An enteric capsule is coated to resist stomach acid, so it passes through the stomach intact and releases its contents lower in the GI tract. The rationale for NMN is that it may be acid-sensitive, so bypassing the stomach could protect more of the dose and improve absorption. Renue's SLC delayed-release format is built around exactly that idea. The honest qualifier: it's a plausible, mechanistically sensible advantage, but it is not robustly proven for NMN in human trials — so treat the delivery tech as a reasonable bet, not a demonstrated absorption upgrade.

Renue prioritizes the delivery format over raw dose. At 250 mg per enteric capsule it's a lower per-capsule dose than the 500 mg single-caps (ProHealth #1, Partiqlar #4) or the 1200 mg high-dose pick (Toniiq #3). The trade is deliberate: you're paying for the enteric SLC delivery rather than maximum milligrams. The upside is that the moderate dose makes the 60-count a full two-month supply. If raw milligrams matter more to you than delivery tech, the 500 mg single-caps are the better fit.

It depends on how you weigh a plausible-but-unproven benefit. If you find the acid-protection rationale compelling and want the most thought-through delivery format in the lineup, Renue is the pick — it's the best FORM here, from a brand that specializes in NAD+ delivery. If you'd rather not pay for a benefit that hasn't been robustly demonstrated in humans, a high-purity standard capsule like Partiqlar (#4) gives you more NMN per dollar in a simpler format. Both are defensible; Renue is the choice for the delivery-first buyer.

Renue By Science is a longevity-focused brand with an unusually deep bench of NAD+ delivery formats (capsules, liposomal, sublingual and more), and the listing states USA manufacturing and third-party testing. That specialization is a genuine credibility point — this is a company built around NAD+ precursors, not a generalist. The honest limit, shared with most of the category: no specific purity percentage is stated and there's no independent NSF/USP seal on the listing, so the testing is brand-stated rather than independently certified.

Yes — re-check before buying. Renue is listed at ASIN B0CXDDV7J7, verified at publication, but it's an NMN product under the FDA's late-2022 exclusion stance, which has made Amazon NMN listings volatile (relabeling, recategorization, ASIN rotation). Renue also offers multiple NMN SKUs and delivery formats, so confirm you're on the 250 mg SLC enteric listing specifically. If reliable stock matters more than the delivery tech, the NR alternatives (Tru Niagen #3, Elysium #6) list more stably.

1. [1] Irie 2020 PMID 31685720 — Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. A first-in-human study giving single oral doses of NMN (100, 250, 500 mg) found it was safely metabolized and raised nicotinamide metabolites dose-dependently. Relevant to Renue's 250 mg dose and to the absorption question — oral NMN is metabolized in humans, though this study did not test enteric versus standard delivery.
2. [2] Kimura 2022 PMID 36225528 — Nicotinamide Mononucleotide Is Safely Metabolized and Significantly Reduces Blood Triglyceride Levels in Healthy Individuals. NMN raised blood NAD+ and reduced triglycerides in healthy individuals. Supports the NAD+-raising mechanism Renue's delivery format aims to optimize — while still short of proving the enteric format improves outcomes or that NMN extends lifespan.
3. [3] Yoshino 2021 PMID 33888596 — Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. The headline human NMN trial: 250 mg/day improved muscle insulin sensitivity in prediabetic women — notably the same 250 mg dose Renue delivers per capsule. A surrogate-marker signal in a small cohort, not evidence of extended lifespan or that enteric delivery adds benefit.